Eli Lilly and Company (LLY)
Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion
Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema.
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.
J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure Fears
Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 million for the quarter ended September 30, according to an SEC filing released on Friday.
Investment Advisor Goes All-In on Big Pharma Stock to the Tune of $1.07 Billion, According to Recent Filing
On October 17, 2025, Sapient Capital LLC disclosed a purchase of 259,392 Eli Lilly and Company (LLY -1.94%) shares, for a total transaction value of $193,028,908.
3 Price Catalysts For Eli Lilly
Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or not. An agreement with the US government on tariffs and further positive trial results can spark a rally for LLY.
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of decline. LLY's robust pipeline, expansion into cardiometabolic and oncology adjacencies, and manufacturing readiness support its competitive edge over NVO. Despite near-term gross margin pressures, LLY's valuation is de-risked, and its growth strategy could bolster near-term catalysts from its diversified pipeline.
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
Eli Lilly (LLY) Laps the Stock Market: Here's Why
Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.
Another Surging Pharma Stock to Watch Right Now
Pharmaceutical concern Eli Lilly And Co (NYSE:LLY ) is charging 7.2% higher to trade at $821.20 this afternoon.
Drug-Pricing Deals And Discounted Bets: Why LLY Stock Is A Core Pick In Our Top 10
Eli Lilly stock (NYSE: LLY) surged 5% yesterday, initially driven by news of a Pfizer deal with the White House to lower drug prices in exchange for tariff immunity. Following this, reports surfaced that the broader pharmaceutical companies are in active discussions with the administration regarding discounted drugs.
